President Trump announces a significant agreement with pharmaceutical giants Novo Nordisk and Eli Lilly to reduce the cost of their weight loss drugs, Wegovy and Zepbound. The deal aims to make these drugs more accessible to the public, with a monthly out-of-pocket cost ranging from $50 to $350, depending on dosage and insurance coverage. This marks a substantial improvement from the current list prices exceeding $1,000 per month. The agreement also includes a commitment to make direct-to-consumer pricing available by the end of the year, with Medicare coverage expected to follow in the middle of next year. This initiative is part of Trump's 'most favored nation' push, aiming to lower prescription drug prices and align them with those in other developed nations. However, questions remain about the plan's effectiveness, as Medicare has already set premiums and copays for 2026, and it's unclear how many people will be able to access the drugs under the new deal. The administration has also reached similar pricing agreements with Pfizer and AstraZeneca to reduce costs for certain prescription drugs covered under Medicaid. This development comes as the Biden administration previously proposed expanding Medicare and Medicaid coverage for GLP-1 drugs, which the Trump administration later rejected. The story is ongoing, and updates will be provided as more information becomes available.
